Lab study finds CBD shifts salinomycin toxicity differently across cell lines
Cannabidiol Differentially Modulates Salinomycin Cytotoxicity in Human Cell Lines.
AI Summary
This abstract-based summary describes a laboratory study asking whether cannabidiol (CBD) changes the cytotoxic effects of salinomycin. Researchers tested the compounds alone and in combination in three human cell lines: kidney-derived HEK-293, liver tumor-derived HepG2, and neuroblastoma-derived SH-SY5Y. These were cell experiments, not studies in people or intact organs.
The effect depended on the cell line: CBD attenuated salinomycin’s cytotoxicity in HEK-293 cells, while it enhanced cytotoxicity in the two tumor-derived lines. The reported changes included differences in IC50 values, reactive oxygen species, and measures of cell death. Because all three cell lines were immortalized or tumor-derived, the findings cannot be extrapolated to normal kidney, liver, or neuronal tissue and do not establish a clinical effect. The abstract does not report quantitative effect sizes; these results do not show that CBD is beneficial or harmful in people.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More CBD research papers you might find interesting.
A lab method measures 17 cannabinoids across five hemp product types
CBD showed limited adaptive-functioning differences versus placebo in boys…
NMR profiling finds THC predominates in Moroccan beldia extracts
Explore More Research
Stay informed about the latest cannabis science.